KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $119.7 million.

  • Castle Biosciences' Cash & Equivalents fell 9.89% to $85.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.6 million, marking a year-over-year decrease of 9.89%. This contributed to the annual value of $119.7 million for FY2024, which is 21.11% up from last year.
  • As of FY2024, Castle Biosciences' Cash & Equivalents stood at $119.7 million, which was up 21.11% from $98.8 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Cash & Equivalents peaked at $409.9 million during FY2020, and registered a low of $98.8 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $113.8 million, with a median of $119.7 million in 2024.
  • In the last 5 years, Castle Biosciences' Cash & Equivalents soared by 314.64% in 2020 and then tumbled by 62.70% in 2022.
  • Yearly analysis of 5 years shows Castle Biosciences' Cash & Equivalents stood at $409.9 million in 2020, then declined by 19.57% to $329.6 million in 2021, then tumbled by 62.70% to $122.9 million in 2022, then decreased by 19.61% to $98.8 million in 2023, then rose by 21.11% to $119.7 million in 2024.